keyword
MENU ▼
Read by QxMD icon Read
search

Lucentis

keyword
https://www.readbyqxmd.com/read/29782468/potential-role-of-gut-microbiota-in-als-pathogenesis-and-possible-novel-therapeutic-strategies
#1
Letizia Mazzini, Luca Mogna, Fabiola De Marchi, Angela Amoruso, Marco Pane, Irene Aloisio, Nicole Bozzi Cionci, Francesca Gaggìa, Ausiliatrice Lucenti, Enrica Bersano, Roberto Cantello, Diana Di Gioia, Giovanni Mogna
BACKGROUND: Recent preclinical studies suggest that dysfunction of gastrointestinal tract may play a role in amyotrophic lateral sclerosis (ALS) pathogenesis through a modification of the gut microbiota brain axis. Our study is the first focused on microbiota analysis in ALS patients. AIM: Our aim was to study the main human gut microbial groups and the overall microbial diversity in ALS and healthy subjects. Moreover we have examined the influence of a treatment with a specific bacteriotherapy composed of Lactobacillus strains (Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus salivarius) acting on the gastrointestinal barrier...
May 18, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29779934/real-study-re-treatment-evaluated-on-visual-acuity-for-lucentis-%C3%A2-in-neovascular-amd
#2
D Bellocq, F De Bats, M Rabilloud, L Kodjikian
PURPOSE: To assess the value of a monthly injection of Lucentis® until stable visual acuity (VA) is obtained for three consecutive months without exudation in patients with neovascular age macular degeneration (AMD). METHODS: Prospective, single-center, non-controlled trial including naïve AMD patients with neovascularization. An assessment of VA and a spectral domain optical coherence tomography (SD-OCT) were performed at baseline and every month. Monthly injections of Lucentis® were performed over three months...
May 17, 2018: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/29772250/development-and-validation-of-a-novel-semi-homogenous-clinical-assay-for-quantitation-of-ranibizumab-in-human-serum
#3
John Lowe, Eric Wakshull, Theresa Shek, Anan Chuntharapai, Rebecca Elliott, Jeriza Rusit, Mauricio Maia
Ranibizumab (Lucentis®), a humanized antigen-binding fragment (Fab) monoclonal antibody that blocks VEGF-A activity is currently approved for the treatment of several retinal degenerative diseases. The assessment of drug pharmacokinetics (PK) is essential for evaluating exposure as it relates to drug safety and efficacy. For drugs administered intravitreally, systemic drug levels during the course of clinical studies are typically 100 to 1000-fold lower than those of similar therapeutics dosed intravenously, posing a significant bioanalytical challenge for PK measurements...
May 14, 2018: Journal of Immunological Methods
https://www.readbyqxmd.com/read/29715501/pharmacology-study-of-a-chimeric-decoy-receptor-trap-fusion-protein-on-retina-neovascularization-by-dual-blockage-of-vegf-and-fgf-2
#4
Jing Jiang, Ke Xu, Ling Wang, Wei Xin, Guorui Zhao, Min Huang, Shenjun Li, Xuejing Luan, Jianmin Fang
BACKGROUND: Clinical anti-vascular epithelial growth factor (VEGF) therapy trials faced a major challenge due to upregulated expression of other pro-angiogenic factors, such as fibroblast growth factor-2 (FGF-2). RC28, a novel recombinant dual decoy receptor IgG1 Fc-fusion protein, can block VEGFA and FGF-2 simultaneously. It is designed for the treatment of neovascular age-related macular degeneration and other pathological ocular neovascularization. The present study investigated the prevention efficacy of RC28 on choroidal neovascularization (CNV) in a monkey model and compared to the other mono VEGF antagonists; biodistribution and pharmacokinetics performance were also investigated...
April 28, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29664983/longitudinal-quantification-of-retinal-nonperfusion-in-the-macula-of-eyes-with-retinal-vein-occlusion-receiving-anti-vegf-therapy-secondary-analysis-of-the-wave-randomized-trial
#5
William C Ou, Shaun I R Lampen, Charles C Wykoff
BACKGROUND AND OBJECTIVE: Longitudinal quantification of retinal nonperfusion (RNP) in eyes with retinal vein occlusion (RVO) undergoing anti-vascular endothelial growth factor therapy. PATIENTS AND METHODS: Thirty eyes with ischemic RVO were randomized to ranibizumab (Lucentis; Genentech, South San Francisco, CA) (monotherapy) or ranibizumab plus peripheral laser (combination therapy) in a 12-month, prospective trial. RNP on fluorescein angiography was quantified within the macula through 12 months of follow-up...
April 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29664980/frequency-of-bevacizumab-and-ranibizumab-injections-for-diabetic-macular-edema-in-medicare-beneficiaries
#6
Connie M Wu, Annie M Wu, Paul B Greenberg, Fei Yu, Flora Lum, Anne L Coleman
BACKGROUND AND OBJECTIVE: To describe the frequency and variation of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) use for diabetic macular edema (DME) in the United States. PATIENTS AND METHODS: The authors obtained a 5% sample of Medicare beneficiaries from the Medicare Part B claims files from 2010 to 2013 and identified beneficiaries with DME using the ICD-9-CM code (362...
April 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29651831/does-age-affect-outcome-in-children-with-clavicle-fracture-treated-conservatively-quickdash-and-mrc-evaluation-of-131-consecutive-cases
#7
Vito Pavone, Claudia DE Cristo, Gianluca Testa, Federico Canavese, Ludovico Lucenti, Giuseppe Sessa
BACKGROUND: Non-operative treatment with immobilization is the gold-standard for paediatric clavicular fractures. Purpose of this study is to evaluate functional outcomes and efficacy of non-operative treatment of clavicular fractures in a succession of 131 children. METHODS: Between 2006 and 2012, we treated non-surgically 131 children for a clavicular fracture. All fractures have been classified according to Robinson classification. Clavicle shortening, range of movements and muscular strength through the Medical Research Council (MRC) scale were evaluated...
April 12, 2018: Minerva Pediatrica
https://www.readbyqxmd.com/read/29492680/formulation-stabilization-and-disaggregation-of-bevacizumab-ranibizumab-and-aflibercept-in-dilute-solutions
#8
Steven A Giannos, Edward R Kraft, Zhen-Yang Zhao, Kevin H Merkley, Jiyang Cai
PURPOSE: Studies were conducted to investigate dilute solutions of the monoclonal antibody (mAb) bevacizumab, mAb fragment ranibizumab and fusion protein aflibercept, develop common procedures for formulation of low concentration mAbs and identify a stabilizing formulation for anti-VEGF mAbs for use in in vitro permeation studies. METHODS: Excipient substitutions were screened. The most stabilizing formulation was chosen. Standard dilutions of bevacizumab, ranibizumab and aflibercept were prepared in PBS, manufacturer's formulation, and the new formulation...
February 28, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29452450/-cost-comparison-of-licensed-intravitreal-therapies-for-insufficiently-anti-vegf-responding-fovea-involving-diabetic-macular-edema-in-germany
#9
Aljoscha S Neubauer, Christos Haritoglou, Michael W Ulbig
BACKGROUND: In the treatment of center-involving diabetic macular edema, despite initial therapy with an anti-VEGF compound, an insufficient response may occur. Further therapy options include a switch of anti-VEGF products or to corticosteroid implants, such as Fluocinolone acetonide or Dexamethasone. OBJECTIVES: Firstly, to investigate systematically which evidence-based study data are available describing the efficacy of in-label treatments after primary anti-VEGF treatment, secondly, to investigate which costs go along for the healthcare provider...
February 16, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29336896/targeted-retinal-photocoagulation-for-diabetic-macular-edema-with-peripheral-retinal-nonperfusion-three-year-randomized-dave-trial
#10
David M Brown, William C Ou, Tien P Wong, Rosa Y Kim, Daniel E Croft, Charles C Wykoff
PURPOSE: To evaluate the effect of targeted retinal photocoagulation (TRP) on visual and anatomic outcomes and treatment burden in eyes with diabetic macular edema (DME). DESIGN: Phase I/II prospective, randomized, controlled clinical trial. PARTICIPANTS: Forty eyes of 29 patients with center-involved macular edema secondary to diabetes mellitus. METHODS: Eyes with center-involved DME and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) between 20/32 and 20/320 (Snellen equivalent) were randomized 1:1 to monotherapy with 0...
May 2018: Ophthalmology
https://www.readbyqxmd.com/read/29304262/prn-ranibizumab-in-the-treatment-of-choroidal-neovascularization-secondary-to-ocular-histoplasmosis
#11
Edward H Wood, Ryan J Whitted, Thomas W Stone, Ricky D Isernhagen, William J Wood, Diana M Holcomb, John W Kitchens
BACKGROUND AND OBJECTIVE: Ranibizumab (Lucentis; Genentech, South San Francisco, CA) is used off-label for the treatment of choroidal neovascularization secondary to ocular histoplasmosis syndrome (OHS). This study prospectively evaluates the safety and efficacy of two treatment paradigms utilizing ranibizumab 0.5 mg: one or three initial injections followed by monthly visits with PRN treatment through Month 12. PATIENTS AND METHODS: In this prospective, open-label study, 21 subjects were evaluated monthly and retreated during the pro re nata treatment phase if specific criteria were met, including loss of vision, increase in subretinal fluid, or hemorrhage...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29106768/cyclic-triimidazole-derivatives-intriguing-examples-of-multiple-emissions-and-ultralong-phosphorescence-at-room-temperature
#12
Elena Lucenti, Alessandra Forni, Chiara Botta, Lucia Carlucci, Clelia Giannini, Daniele Marinotto, Alessandro Pavanello, Andrea Previtali, Stefania Righetto, Elena Cariati
The performance of solid luminogens depends on both their inherent electronic properties and their packing status. Intermolecular interactions have been exploited to achieve persistent room-temperature phosphorescence (RTP) from organic molecules. However, the design of organic materials with bright RTP and the rationalization of the role of interchromophoric electronic coupling remain challenging tasks. Cyclic triimidazole has been shown to be a promising scaffold for such purposes owing to its crystallization-induced room-temperature ultralong phosphorescence (RTUP), which has been associated with H-aggregation...
December 18, 2017: Angewandte Chemie
https://www.readbyqxmd.com/read/28954021/alternative-ways-to-optimize-treatment-for-retinal-vein-occlusion-with-peripheral-capillary-non-perfusion-a-pilot-study
#13
COMPARATIVE STUDY
Svetlana N Tultseva, Yury S Astakhov, Sergei A Novikov, Pavel A Nechiporenko, Alla B Lisochkina, Andranik Y Ovnanyan, Sergei Y Astakhov
Purpose: We compared the efficacy and safety of ranibizumab versus ranibizumab plus scatter laser photocoagulation (SLP) in patients with chronic post-central retinal vein occlusion (CRVO) macular edema (ME). Methods: This prospective non-randomized pilot study included 250 patients with peripheral retinal ischemia and CRVO-related ME. The mean follow-up period was 24.5 ± 6.5 months. The clinical assessments conducted included best corrected visual acuity, optical coherence tomography, and multi-field fluorescein angiography with measurement of the ischemic area...
July 2017: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28919773/sickle-cell-retinopathy-improving-care-with-a-multidisciplinary-approach
#14
REVIEW
Farid Menaa, Barkat Ali Khan, Bushra Uzair, Abder Menaa
Sickle cell retinopathy (SCR) is the most representative ophthalmologic complication of sickle cell disease (SCD), a hemoglobinopathy affecting both adults and children. SCR presents a wide spectrum of manifestations and may even lead to irreversible vision loss if not properly diagnosed and treated at the earliest. Over the past decade, multidisciplinary research developments have focused upon systemic, genetic, and ocular risk factors of SCR, enabling the clinician to better diagnose and manage these patients...
2017: Journal of Multidisciplinary Healthcare
https://www.readbyqxmd.com/read/28846476/identification-of-multiple-serine-to-asparagine-sequence-variation-sites-in-an-intended-copy-product-of-lucentis%C3%A2-by-mass-spectrometry
#15
François Griaud, Andrej Winter, Blandine Denefeld, Manuel Lang, Héloïse Hensinger, Frank Straube, Mirko Sackewitz, Matthias Berg
Patent expiration of first-generation biologics and the high cost of innovative biologics are 2 drivers for the development of biosimilar products. There are, however, technical challenges to the production of exact copies of such large molecules. In this study, we performed a head-to-head comparison between the originator anti-VEGF-A Fab product LUCENTIS® (ranibizumab) and an intended copy product using an integrated analytical approach. While no differences could be observed using size-exclusion chromatography, capillary electrophoresis-sodium dodecyl sulfate and potency assays, different acidic peaks were identified with cation ion exchange chromatography and capillary zone electrophoresis...
November 2017: MAbs
https://www.readbyqxmd.com/read/28845845/lucentis-%C3%A2-ranibizumab-abbreviated-uk-prescribing-information
#16
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Eye
https://www.readbyqxmd.com/read/28809980/stimuli-responsive-nlo-properties-of-tetrathiafulvalene-fused-donor-acceptor-chromophores
#17
E Cariati, X Liu, Y Geng, A Forni, E Lucenti, S Righetto, S Decurtins, S-X Liu
The second-order nonlinear optical (NLO) properties of two tetrathiafulvalene (TTF)-fused electron donor-acceptor dyads have been determined using the Electric Field Induced Second Harmonic generation (EFISH) technique and theoretically rationalized. Dyads TTF-dppz (1) and TTF-BTD (2) were obtained by direct fusion of a TTF electron donor unit either with a dipyrido[3,2-a:2',3'-c]phenazine (dppz) or a benzothiadiazole (BTD) electron acceptor moiety. Dyad 1 acts as a reversible acido-triggered NLO switch by protonation/deprotonation at two nitrogen atoms of the dppz acceptor moiety induced by sequential exposure to HCl and ammonia vapors...
August 23, 2017: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/28736371/-multifocal-electroretinography-for-therapeutic-effect-evaluation-of-intravitreal-injection-lucentis-for-wet-age-related-macular-degeneration
#18
Rui-Hong Ju, Man-Sha He, Jin-Tong Hou, Meng-Yuan Li, Jing-Lin Zhang, Zhe-Ming Wu
OBJECTIVE: To evaluate the changes in retinal functions using multifocal electroretinography (mfERG) following intravitreal injection of Lucentis for treatment of wet age-related macular degeneration. METHODS: This prospective study was conducted in 14 patients (9 men and 5 women, 14 eyes) with wet age-related macular degeneration receiving treatment with intravitreal injections of ranibizumab (Lucentis) in our hospital between October, 2014 and January, 2016. All the patients received the treatment following a 1+PRN protocol and after the initial injection, the patients were followed up monthly for 6 months to decide if additional injections were needed...
July 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28654629/predictors-of-one-year-visual-outcomes-after-anti-vascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#19
Laurent Kodjikian, Evelyne Decullier, Eric H Souied, Adeline Roux, Gilles Aulagner, Laure Huot
PURPOSE: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). METHODS: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen)...
June 20, 2017: Retina
https://www.readbyqxmd.com/read/28613352/comparison-of-ranibizumab-and-bevacizumab-for-macular-edema-secondary-to-retinal-vein-occlusions-in-routine-clinical-practice
#20
Mehnaz Khan, Karen M Wai, Fabiana Q Silva, Sunil Srivastava, Justis P Ehlers, Aleksandra Rachitskaya, Amy Babiuch, Ryan Deasy, Peter K Kaiser, Andrew P Schachat, Alex Yuan, Rishi P Singh
BACKGROUND AND OBJECTIVE: To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS: A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated...
June 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"